• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

MEDS Interim Report Q1 2026: Increased market share while margins strengthened from Q4

Meds Apotek
Download the release

January – March 2026

  • Net sales increased by 12% (29%) to SEK 270 million (242).
  • Operating profit (EBIT) was SEK 5.2 million (5.5), corresponding to an EBIT margin of 1.9% (2.3%).
  • Earnings per share before dilution were SEK 0.27 (0.31).
  • Cash flow from operating activities was SEK 35.3 million (16.7).
  • Cash flow for the period was SEK 26.4 million (12.9).
  • Cash and cash equivalents totaled SEK 71.5 million at the end of the period.

Björn Thorngren, CEO, comments:

"The first quarter of 2026 demonstrates strong continued growth, particularly in prescription medicines, and improved profitability compared to Q4. We are gaining market share and growing our customer base."

"The trend is clear and stable - more and more Swedes are choosing to have their medication delivered at home rather than visiting a physical pharmacy."

"Work on our new logistics center is progressing according to plan. The facility nearly triples our warehouse space and gives us capacity to grow for a long time to come. We are also investing in further strengthened automation capacity within packing and order sorting."

The results for the period January – March 2026 will be presented by MEDS CEO Björn Thorngren and CFO Nick Mendola today at 09:30 CEST. The presentation will be held in English. Please contact ir@meds.se to receive a link to the presentation (at latest 09:00 CEST today).

For further information, please contact:
Press contact, email: press@meds.se
IR contact, email: ir@meds.se

About MEDS
MEDS, launched in 2018, is a full-scale online pharmacy licensed by the Swedish Medical Products Agency, operating in the Swedish market. MEDS offers customers prescription medicines, over-the-counter medicines, and a wide range of pharmacy-related products. As of March 31, 2026, the company had more than 1 million active customers. Net sales for the past twelve months, as of March 31, 2026, amounted to approximately SEK 1 034 million. The company’s headquarters are in Stockholm, and as of March 31, 2026, the number of FTE employees was 49.

This information is information that MEDS Apotek AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-05-05 07:30 CEST.

Attachments


Meds Apotek Group Interim Report Q1 2026 ENG